BofA initiated coverage of CG Oncology with a Buy rating and $65 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGON:
- CG Oncology initiates EAP for Cretostimogene Grenadenorepvec in U.S.
- CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
- CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
- CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
- CG Oncology upgraded to Buy from Neutral at Goldman Sachs